SAMHSA Relaxes Regulations on Methadone and Buprenorphine During COVID-19 Emergency
The Carlat Addiction Treatment Report, Volume 8, Number 3&4, May 2020
https://www.thecarlatreport.com/newsletter-issue/catrv8n3-4/
Issue Links: Learning Objectives | Editorial Information
Topics: Buprenorphine | Coronavirus | COVID-19 | Methadone | Opioid epidemic | Opioid Use Disorder | Opioids | Outpatient | pandemic | Patient relationship
Benjamin Oldfield
Editor-in-Chief of CATR. Clinical Instructor in Medicine and Pediatrics at Yale School of Medicine; Chief Medical Officer at Fair Haven Community Health Care, CT.
Dr. Oldfield has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
In the context of a pandemic, how can and should our practices change to continue to meet the needs of patients with opioid use disorder? We summarize recent changes to the regulations surrounding medications for opioid use disorder: buprenorphine and methadone.
You can't view details of this content, please login or buy subscription here